Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Donanemab raised the risk of amyloid-related imaging abnormalities (ARIA) in Alzheimer's patients. Many ARIA events ...

But some experts say the side effects of the drug called donanemab may outweigh its benefits. It was given the green light by UK drug regulators, the Medicines and Healthcare Products Regulatory ...

But some experts have long warned that side effects of the drug — called donanemab — massively outweigh its benefits. Now, a new study from the company that produces the medication itself ...

Headlines about the results of TRAILBLAZER-ALZ2 trial of Eli Lilly’s Alzheimer’s drug candidate donanemab are spreading around the world, with some going as far as to suggest this could herald ...

The purpose of many compounds developed as potential treatments for Alzheimer's disease in recent years is to reduce the accumulation of amyloid-β peptide (Aβ) in the brain, a hallmark of the ...

Lilly is seeking approval for donanemab in early-stage Alzheimer's, and is hoping to get a speedy FDA green light on the back of amyloid clearance data as a surrogate marker for clinical efficacy ...

While researchers continue to work on a full cure for Alzheimer's disease, they're finding treatments that can help manage symptoms and delay their onset, including the recently approved next-gen ...

However, its approval has been met with controversy due to debates over its clinical efficacy and associated risks. Donanemab, developed by Eli Lilly, is another promising monoclonal antibody ...

Activities the person can engage with and enjoy might also help. These could include reminiscence therapy, spending time outside, and singing. Some people with dementia may find one of these therapies ...